BACKGROUND

OBJECTIVES
•
The objective of this research was to collect qualitative patient data to identify the most important clinical attributes and outcomes of pharmacological treatments for bipolar depression that influence patients' treatment adherence decisions.
• Qualitative results will guide the development of a quantitative discrete choice experiment to determine patient preferences and willingness to trade off between medication characteristics.
METHODS
• Bipolar disorder is characterized by periods of clinical depression alternating with periods of mania. The majority of patients with bipolar disorder spend more time in depressive episodes than the manic state, including subsyndromal depressive symptoms. (Vieta & Valentí 2013) • Patients' preferences with regard to treatment for bipolar depression has not been well studied.
• Understanding patients' preferences for bipolar depression treatments may enhance treatment adherence and treatment outcomes.
Background Work -Literature Review • The most recently approved prescribing information for 29 first-and second-generation antipsychotics, mood stabilizers, and anticonvulsants were reviewed to identify information on treatment attributes for bipolar disorder, including treatment efficacy, clinical outcomes, and adverse effects.
• A review of the literature was conducted on articles published between 2009 and 2014 that discussed treatment efficacy, adverse reactions, treatment adherence, and patient satisfaction associated with treatments for bipolar depression. Background Work -Clinical Expert Interview • An expert interview was conducted with a clinical psychiatrist to identify key issues and concerns in bipolar depression regarding treatment outcomes, with an emphasis on treatment side effects and reasons for continuing/discontinuing treatment.
Summary of Background Work •
Results from the literature, prescribing information review, and clinical expert interview guided the development of the focus group discussion guide, and will also inform the development of treatment attributes and levels for inclusion in a future discrete choice experiment to assess patients' preferences for treatment of bipolar depression. The MADRS-S includes nine items assessing depressive symptoms rated on a severity scale of 0-6. The total score is obtained by summing the ratings of all nine items (possible range: 0-54), with higher scores indicating greater depression.
Patient Focus Groups
-
The WHO-5 consists of five items assessing emotional well-being rated on a six-point scale, ranging from 0 (not present) to 5 (constantly present). Raw scores are summed and transformed into a percentage score (possible range: 0-100%), with higher scores indicating better quality of life. -The PROMIS Global Health Scale includes 10 questions covering the global domains of physical health and mental health. Global and Physical Health component scores were calculated and converted into a T-score (possible range for physical T-score: 16.2-67.7; possible range for mental T-score: 21.2-67.6), which is standardized such that a score of 50±10 represents the mean for the US general population, with higher scores representing better health.
•
Clinical site staff completed a clinical characteristics questionnaire that collected information about the patient's bipolar depression diagnosis, treatment history, and comorbid conditions. Data Analysis • Quantitative data (sociodemographic, clinical, and patient-reported outcomes) were summarized descriptively.
• Focus group audio-recordings were transcribed, a data coding dictionary was developed, and ATLAS.ti software was used for qualitative data analysis.
• Qualitative data were analyzed for themes that patients described related to their expectations and preferences for bipolar depression treatment features, efficacy, and adverse events. The mean±SD WHO-5 raw score was 11.2±5.1, which translates into a mean±SD WHO-5 percentage score of 44.8%±20.6% (range 16.0%-80.0%).
RESULTS
•
The mean±SD PROMIS Global Physical Health summary T-score was 39.8±8.3, and the mean±SD Global Mental Health summary T-score was 39.8±7.3. Scores indicate poorer physical and mental health, respectively, in the current study population when compared to the general US population (Figure 1 ).
Focus Group Discussion
• Participants reported different types of discussions with their doctors related to treatment expectations and concerns. More than half reported they had discussed their bipolar symptoms, including depression (n=9, 56%), half discussed side effects (n=8, 50%), and more than one third discussed their treatment regimen (n=6, 38%) with their doctors.
•
No participants reported involving family members or persons other than their doctors in treatment decisions. • When asked to describe which attributes of treatment were most important, participants were most concerned with treatment efficacy, expecting a medication to balance the "highs and lows" of bipolar symptoms, and providing "clarity" (control of thoughts and actions).
• With regard to dosing frequency, participants generally preferred fewer medication doses per day (i.e., once a day) or a treatment regimen comprising few pills or one pill per dose. Such regimens were preferred, as it made it easier to remember to take their medication or because they fit better in the participant's daily routine.
• Dosing adjustment was not found to impact participants' decisions to take a treatment, as most participants did not specify a preference (n=15, 94%). Three participants (19%) stated that having regular blood tests did not impact their decisions to stay on a treatment, while the remainder did not specify a preference (n=13, 81%).
• Four participants (25%) expected symptom improvements within two weeks of treatment initiation and would tolerate side effects and less desirable features, as long as these did not outweigh treatment benefits (Table 2) .
Characteristics N=16
Age ( 
I was on a medication that just blew my, ah, cholesterol level just super high and after the first week my doctor noticed and he tried to modify it. Didn't take me off the medication but told me to stop eating dairy products. But you know, it modified it a little bit but he kept me still on the high levels, so finally he took me off. I ended up getting the high cholesterol
Nervous System
Sedation 9 (56%)
To just, whether I'm going to be early or if I'm getting a good night's sleep, if I have something to do the next day, like I only take 100 because I didn't want to wake up in a fog because usually it takes me about 2 hours to wake up. I'll just be sitting there spacing out drinking coffee One pill equals 24 straight in bed. Then when I get up, I'm still high. I'm stumbling and falling over.
Dry Mouth 5 (31%)
Then I go to a higher dose and I'm getting cotton mouth Me, too. I got dry mouth and I got cramps in my stomach. • In terms of adverse events, weight gain, sedation, tremors, becoming manic, high glucose levels, and high cholesterol were the most commonly noted by participants as having the greatest influence on their treatment decisions. Other side effects of bipolar depression treatments were also discussed (Table 3 ).
• To manage side effects, almost half of the participants (n=7, 44%) reported reducing dosage or discontinuing treatment without medical consultation. Experiencing sedation was a common reason for altering a treatment dosage (Table 4 ).
• Based on the focus groups, the three most important outcomes determining patients' treatment decisions were: treatment efficacy/time to symptom improvement, risk of weight gain, and sedation/fatigue. • Almost half of participants reported adjusting or stopping bipolar depression treatment to manage side effects without medical consultation.
• Based on the literature, product inserts, clinician feedback, and focus group results, a list of the most important and clinically relevant treatment attributes will be included in a future quantitative discrete choice experiment to determine patients' preferences for bipolar depression pharmacological treatments.
The treatment attribute list may include: time to symptom improvement, risk of becoming manic, weight gain, risk of sedation, increased blood glucose, and increased cholesterol.
•
Results from this focus group study and the future discrete choice experiment study may provide useful information for physicians to discuss treatment options with patients based on their preferences and expectations, and ultimately improve treatment adherence.
Bipolar Depression Treatment Attribute Rating Task
• In the Attribute Rating Task, participants were asked to rate various treatment features and outcomes on a scale of 0-3, with higher ratings indicating greater importance of the outcome or feature in influencing a participant's treatment decision.
•
The three most important treatment outcomes/features that would influence participants' treatment decisions were tremors/rigidity (mean rating: 3.0±0.0), fainting (mean rating: 2.9±0.5), and cardiac side effects (mean rating: 2.9±0.3). However, there was little variation in the ratings of most adverse effects (range 2.1-3.0).
* n=15 due to missing responses; ** T-scores standardized such that a score of 50±10 represents the mean for the US general population, with higher scores representing better health. 
